Publications by authors named "Herman Burger"

Claim this Profile
I
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Erik A C Wiemer, Agnieszka Wozniak, Herman Burger, Marcel Smid, Giuseppe Floris

Eur J Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Ellen S de Morrée, René Böttcher, Robert J van Soest, Ashraf Aghai, Corrina M de Ridder, Herman Burger

Br J Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
Ellen de Morrée, Robert van Soest, Ashraf Aghai, Corrina de Ridder, Peter de Bruijn, Herman Burger

Prostate· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysosomal Sequestration Determines Intracellular Imatinib Levels.
Herman Burger, Alexander T den Dekker, Sandra Segeletz, Antonius W M Boersma, Peter de Bruijn

Mol Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Jacqueline S L Kloth, Lisette Binkhorst, Annelieke S de Wit, Peter de Bruijn, Paul Hamberg, Herman Burger

Clin Pharmacokinet· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Lisette Binkhorst, Jacqueline S L Kloth, Annelieke S de Wit, Peter de Bruijn, Mei H Lam, Herman Burger

Breast Cancer Res Treat· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors.
Diane A J van der Biessen, Herman Burger, Peter de Bruijn, Cor H J Lamers, Nicole Naus

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Ferry A L M Eskens, Francisco J Ramos, Herman Burger, James P O'Brien, Adelaida Piera

Clin Cancer Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
Herman Burger, Ron H J Mathijssen, Alex Sparreboom, Erik A C Wiemer

Blood· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
John Marshall, Jimmy Hwang, Ferry A L M Eskens, Herman Burger, Shakun Malik

Invest New Drugs· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Ferry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M Cotreau, Herman Burger

Clin Cancer Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug transporters and imatinib treatment: implications for clinical practice.
Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M Franke, Gaia Schiavon

Clin Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug transporters of platinum-based anticancer agents and their clinical significance.
Herman Burger, Walter J Loos, Karel Eechoute, Jaap Verweij, Ron H J Mathijssen

Drug Resist Updat· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
Maja J A de Jonge, Marije Slingerland, Walter J Loos, Erik A C Wiemer, Herman Burger

Eur J Cancer· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction of imatinib with human organic ion carriers.
Shuiying Hu, Ryan M Franke, Kelly K Filipski, Chaoxin Hu, Shelley J Orwick, Herman Burger

Clin Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Jozien Helleman, Herman Burger, Irene H L Hamelers, Antonius W M Boersma, Anton I P M de Kroon

Cancer Biol Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Erin R Gardner, Herman Burger, Ron H van Schaik, Allan T van Oosterom, Ernst A de Bruijn

Clin Pharmacol Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Herman Burger, Michael A den Bakker, Johan M Kros, Hans van Tol, Alex M de Bruin

Cancer Biol Ther· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Herman Burger, Hans van Tol, Mariël Brok, Erik A C Wiemer, Ernst A de Bruijn

Cancer Biol Ther· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Alex Sparreboom, Walter J Loos, Herman Burger, Tristan M Sissung, Jaap Verweij

Cancer Biol Ther· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib.
Herman Burger, Kees Nooter

Cell Cycle· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Herman Burger, Hans van Tol, Antonius W M Boersma, Mariël Brok, Erik A C Wiemer

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.
Paul W Schenk, Mariel Brok, Antonius W M Boersma, Jourica A Brandsma, Hans Den Dulk, Herman Burger

Mol Pharmacol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Herman Burger, John A Foekens, Maxime P Look, Marion E Meijer-van Gelder, Jan G M Klijn

Clin Cancer Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype.
Paul W Schenk, Antonius W M Boersma, Mariël Brok, Herman Burger, Gerrit Stoter

Mol Pharmacol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis